TipRanks
Advertisement
Advertisement
Compass Therapeutics price target lowered to $4 from $8 at Guggenheim
PremiumThe FlyCompass Therapeutics price target lowered to $4 from $8 at Guggenheim
27d ago
Compass Therapeutics price target lowered to $12 from $24 at H.C. Wainwright
Premium
The Fly
Compass Therapeutics price target lowered to $12 from $24 at H.C. Wainwright
27d ago
Compass Therapeutics price target lowered to $4 from $10 at Citizens
Premium
The Fly
Compass Therapeutics price target lowered to $4 from $10 at Citizens
27d ago
Compass Therapeutics says FDA requests new trial for tovecimig
PremiumThe FlyCompass Therapeutics says FDA requests new trial for tovecimig
28d ago
Analyst Reiterates Buy on Compass Therapeutics Ahead of Key FDA Catalyst; $7 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on Compass Therapeutics Ahead of Key FDA Catalyst; $7 Price Target Maintained
2M ago
Compass Therapeutics price target raised to $7 from $4 at Leerink
Premium
The Fly
Compass Therapeutics price target raised to $7 from $4 at Leerink
2M ago
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
PremiumRatingsCompass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
6M ago
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
Premium
The Fly
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
6M ago
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
Premium
The Fly
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
6M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―